Trial | NCT00149552  Report issue

Title

Zinc Therapy in HIV Infected Individuals Who Abuse Drugs
Zinc Therapy in Zinc Deficient HIV Positive Drug Users

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    zinc ...

  • Study Participants

    231
Zinc deficiency is prevalent in HIV infected individuals who abuse drugs. The purpose of this study is to determine if zinc therapy will prevent immune failure in HIV infected individuals who abuse drugs and have low plasma zinc levels.
Low levels of zinc are associated with an increased risk of HIV-related death and opportunistic infections in HIV infected individuals. Drug users are especially susceptible to zinc deficiency. The purpose of this trial is to evaluate the effectiveness of zinc therapy in preventing immune failure in HIV infected individuals who abuse drugs.

This trial will last 30 months. Participants will be randomly assigned to receive either zinc supplements or placebo. Male participants will receive 15 mg of zinc and female participants will receive 12 mg of zinc. Clinical and laboratory study visits will occur at 3 or 6 month intervals throughout the study.
Study Started
Jun 30
2001
Study Completion
Jan 31
2007
Last Update
Mar 05
2012
Estimate

Dietary Supplement zinc

supplementation with zinc gluconate

Zinc gluconate Active Comparator

Zinc supplementation

  • Dietary Supplement zinc

Placebo Placebo Comparator

Placebo

  • Dietary Supplement zinc

Criteria 

Inclusion Criteria:

HIV infected
Drug User
Blood zinc level greater than 0.35 mcg/mL and less than 0.75mcg/ml

Exclusion Criteria:

Currently participating in an another clinical trial
Blood selenium level less than 85 mcg/L
Pregnant or intends to become pregnant
No Results Posted